Back to Browse Journals » OncoTargets and Therapy » Volume 2

Targeting cancers in the gastrointestinal tract: role of capecitabine

Authors Muhammad Wasif Saif

Published 25 March 2009 Volume 2009:2 Pages 29—41


Review by Single-blind

Peer reviewer comments 2

Muhammad Wasif Saif

Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA

Abstract: Capecitabine is currently the only novel, orally home-administered fluorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors, including breast cancer, colorectal cancer, gastric cancer, and many others. Furthermore, the drug compares favorably with fluorouracil in patients with such cancers, with a safe toxicity profile, consisting mainly of gastrointestinal and dermatologic adverse effects. Whereas gastrointestinal events and hand-foot syndrome occur often with capecitabine, the tolerability profile is comparatively favorable. Prompt recognition of severe adverse effects is the key to successful management of capecitabine. Ongoing and future clinical trials will continue to examine, and likely expand, the role of capecitabine as a single agent and/or in combination with other anticancer agents for the treatment of gastrointestinal as well as other solid tumors, both in the advanced palliative and adjuvant settings. The author summarizes the current data on the role of capecitabine in the management of gastrointestinal cancers.

Keywords: 5-fluorouracil, capecitabine, chemotherapy, adjuvant, advanced, colon cancer, gastric cancer, hepatocellular cancer, pancreatic cancer, cholangiocarcinoma, rectal cancer, anal cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

Jia Li, Muhammad Wasif Saif

Biologics: Targets and Therapy 2009, 3:429-441

Published Date: 7 September 2009

Readers of this article also read:

Polymeric nanoparticles enhance the sonodynamic activity of meso-tetrakis (4-sulfonatophenyl) porphyrin in an in vitro neuroblastoma model

Canaparo R, Varchi G, Ballestri M, Foglietta F, Sotgiu G, Guerrini A, Francovich A, Civera P, Frairia R, Serpe L

International Journal of Nanomedicine 2013, 8:4247-4263

Published Date: 6 November 2013

A dynamic magnetic shift method to increase nanoparticle concentration in cancer metastases: a feasibility study using simulations on autopsy specimens

Nacev A, Kim SH, Rodriguez-Canales J, Tangrea MA, Shapiro B, Emmert-Buck MR

International Journal of Nanomedicine 2011, 6:2907-2923

Published Date: 18 November 2011

Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia

Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A

OncoTargets and Therapy 2011, 4:149-168

Published Date: 5 September 2011

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib

Massimo Breccia, Giuliana Alimena

OncoTargets and Therapy 2008, 1:49-58

Published Date: 17 October 2008